Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID infection severity in children under 5 years old before and after Omicron emergence in the US

Lindsey Wang, Nathan A. Berger, David C. Kaelber, View ORCID ProfilePamela B. Davis, View ORCID ProfileNora D. Volkow, View ORCID ProfileRong Xu
doi: https://doi.org/10.1101/2022.01.12.22269179
Lindsey Wang
1Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA
2Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan A. Berger
2Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, OH, USA
3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Kaelber
4The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela B. Davis
5Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pamela B. Davis
Nora D. Volkow
6National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nora D. Volkow
Rong Xu
1Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA
3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rong Xu
  • For correspondence: rxx@case.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Pediatric SARS-CoV-2 infections and hospitalizations are rising in the US and other countries after the emergence of Omicron variant. However data on disease severity from Omicron compared with Delta in children under 5 in the US is lacking.

Objectives To compare severity of clinic outcomes in children under 5 who contracted COVID infection for the first time before and after the emergence of Omicron in the US.

Design, Setting, and Participants This is a retrospective cohort study of electronic health record (EHR) data of 79,592 children under 5 who contracted SARS-CoV-2 infection for the first time, including 7,201 infected between 12/26/2021-1/6/2022 when the Omicron predominated (Omicron cohort), 63,203 infected between 9/1/2021-11/15/2021 when the Delta predominated (Delta cohort), and another 9,188 infected between 11/16/2021-11/30/2021 when the Delta predominated but immediately before the Omicron variant was detected in the US (Delta-2 cohort).

Exposures First time infection of SARS-CoV-2.

Main Outcomes and Measures After propensity-score matching, severity of COVID infections including emergency department (ED) visits, hospitalizations, intensive care unit (ICU) admissions, and mechanical ventilation use in the 3-day time-window following SARS-CoV-2 infection were compared between Omicron and Delta cohorts, and between Delta-2 and Delta cohorts. Risk ratios, and 95% confidence intervals (CI) were calculated.

Results Among 7,201 infected children in the Omicron cohort (average age, 1.49 ± 1.42 years), 47.4% were female, 2.4% Asian, 26.1% Black, 13.7% Hispanic, and 44.0% White. Before propensity score matching, the Omicron cohort were younger than the Delta cohort (average age 1.49 vs 1.73 years), comprised of more Black children, and had fewer comorbidities. After propensity-score matching for demographics, socio-economic determinants of health, comorbidities and medications, risks for severe clinical outcomes in the Omicron cohort were significantly lower than those in the Delta cohort: ED visits: 18.83% vs. 26.67% (risk ratio or RR: 0.71 [0.66-0.75]); hospitalizations: 1.04% vs. 3.14% (RR: 0.33 [0.26-0.43]); ICU admissions: 0.14% vs. 0.43% (RR: 0.32 [0.16-0.66]); mechanical ventilation: 0.33% vs. 1.15% (RR: 0.29 [0.18-0.46]). Control studies comparing Delta-2 to Delta cohorts show no difference.

Conclusions and Relevance For children under age 5, first time SARS-CoV-2 infections occurring when the Omicron predominated (prevalence >92%) was associated with significantly less severe outcomes than first-time infections in similar children when the Delta variant predominated.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

National Institute on Aging (grants nos. AG057557, AG061388, AG062272), National Institute on Alcohol Abuse and Alcoholism (grant no. R01AA029831), National Institute on Drug Abuse (grant no. UG1DA049435), the Clinical and Translational Science Collaborative (CTSC) of Cleveland (grant no. 1UL1TR002548-01), National Cancer Institute Case Comprehensive Cancer Center (R25CA221718, P30 CA043703, P20 CA2332216).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The details of the IRB/oversight body that provided approval or exemption for the research described are given below: TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2013 standard and maintains an Information Security Management System (ISMS) to ensure the protection of the healthcare data it has access to and to meet the requirements of the HIPAA Security Rule. Any data displayed on the TriNetX Platform in aggregate form, or any patient level data provided in a data set generated by the TriNetX Platform, only contains de-identified data as per the de-identification standard defined in Section 164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section 164.514(b)(1) of the HIPAA Privacy Rule (reference). This formal determination by a qualified expert, refreshed in December 2020, supersedes the need for TriNetX's previous waiver from the Western Institutional Review Board (IRB). Because we only used de-identified data, we did not seek nor did we obtain Institutional Board Approval for this research. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. We have another TriNetX study published through medRxiv. It can be found at: https://www.medrxiv.org/content/10.1101/2021.12.30.21268495v1

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 13, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID infection severity in children under 5 years old before and after Omicron emergence in the US
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID infection severity in children under 5 years old before and after Omicron emergence in the US
Lindsey Wang, Nathan A. Berger, David C. Kaelber, Pamela B. Davis, Nora D. Volkow, Rong Xu
medRxiv 2022.01.12.22269179; doi: https://doi.org/10.1101/2022.01.12.22269179
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
COVID infection severity in children under 5 years old before and after Omicron emergence in the US
Lindsey Wang, Nathan A. Berger, David C. Kaelber, Pamela B. Davis, Nora D. Volkow, Rong Xu
medRxiv 2022.01.12.22269179; doi: https://doi.org/10.1101/2022.01.12.22269179

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1435)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10334)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2654)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (571)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1335)
  • Ophthalmology (403)
  • Orthopedics (153)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2421)
  • Public and Global Health (5032)
  • Radiology and Imaging (902)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)